Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 28 of 28 publications.
Skip to main content
Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.
Boeri M, Marcek T, Chintakayala PK, Poulos C, Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S. Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S313. doi: 10.1016/j.jval.2023.09.1653
Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Samant S, Oberle S, Marcek T, Poulos C, Chintakayala PK, Langevin E, Petigara T, Boeri M. Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S318-9. doi: 10.1016/j.jval.2023.09.1679
Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Orphanet J Rare Dis. 2023 Nov 2;18(1):343. doi: 10.1186/s13023-023-02957-2
Perrone RD, Nunna S, Gandhi HK, Fernandes AW, Garbinsky D, Zhou X. Kidney function decline in autosomal dominant polycystic kidney disease (ADPKD) patients: assessment of real world effectiveness of tolvaptan. Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
McErlane F, Boeri M, Bussberg C, Cappelleri JC, Germino R, Stockert L, Vass C, Huber AM. Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: a discrete-choice experiment. Pediatr Rheumatol Online J. 2023 Oct 21;21(1):129. doi: 10.1186/s12969-023-00906-8
Li D, Tan A, Hernandez S, Reilly N, Bussberg CJ, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments. Poster presented at the 20th Annual International Society of Gastrointestinal Oncology; October 13, 2023. Tempe, AZ. Previously presented at the ESMO 24th World Congress on Gastrointestinal Cancer 2022.
Frederiksen KS, Crawford R, Hahn-Pedersen J, Morrison R, Jeppesen R, Doward L, Weidner W. “Don't you recognize me...?”: insights from social media posts on the impact of alzheimer's disease on care partners. Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.
Stothers Rosenberg S, Ng X, Mansfield C, Poulos C, Peay H, Lee TH, Irony T, Ho M. Adaptation of the WOMAC for use in a patient preference study. Ther Innov Regul Sci. 2023 Jul;57(4):702-11. doi: 10.1007/s43441-023-00510-8
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Pooled data analysis of the effect of tolvaptan in patients aged 18-35 years with autosomal dominant polycystic kidney disease. Poster presented at the PKD Connect Conference 2023; June 23, 2023. Denver, CO.
Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Neurol. 2023 Jun 22;24:182. doi: 10.1186/s12882-023-03247-6
Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease (ADPKD). Poster presented at the 51st Annual Meeting of the European Working Group on Psychosocial Aspects of Children; June 8, 2023. Leuven, Belgium. Previously presented at the National Kidney Foundation 2023 Spring Clinical Meeting.
Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378
Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia or bipolar I disorder. Poster presented at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 30, 2023. Miami Beach, FL.
Doane MJ, Boeri M, Vass CM, Bussberg CJ, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia. Poster presented at the SIRS 2023 Congress; May 13, 2023. Toronto, Canada.
Maeda-Chubachi T, McLeod L, Cartwright M. Meaningful change in children's dermatology life quality index (DLQI) and lesion counts in patients with molluscum contagiosum. Poster presented at the First International Societies for Investigative Dermatology (ISID2023) Meeting; May 10, 2023. Tokyo, Japan. [abstract] J Invest Dermatol. 2023 May; 143(5 Suppl):S105. doi: 10.1016/j.jid.2023.03.622
Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0
Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349
Bhattacharya R, Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Calhoun SR, Poulos C. Exploring perceptions of the risk of recurrence in renal cell carcinoma: evidence from a survey of practicing physicians. Poster presented at the 2023 American Urological Association Annual Meeting; April 28, 2023. Chicago, IL. [abstract] J Urol. 2023 Apr 1; 209(Supplement 4):e271. doi: 10.1097/JU.0000000000003244.15
Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):661. doi: 10.1200/JCO.2023.41.6_suppl.661
Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient and physician preferences for adjuvant treatment of renal cell carcinoma: a discrete-choice experiment. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):635. doi: 10.1200/JCO.2023.41.6_suppl.635
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GA, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clement K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023 Jan 16;18(1):12. doi: 10.1186/s13023-022-02602-4
Kandzari DE, Weber MA, Poulos C, Coulter J, Cohen SA, DeBruin V, Jones D, Pathak A. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023 Jan;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997
Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006